1 / 41

FUTURE RESEARCH IN SUBSTANCE MISUSE AN OVERVIEVW PERSPECTIVE

FUTURE RESEARCH IN SUBSTANCE MISUSE AN OVERVIEVW PERSPECTIVE. Michael Farrell PHRN Manchester 20 th October 2006. Political and moral values of the social system . SERVICE Provider AND USER VIEW. Research Evidence. A model for evidence-based clinical decisions (from Haynes et al, 1996).

wiley
Download Presentation

FUTURE RESEARCH IN SUBSTANCE MISUSE AN OVERVIEVW PERSPECTIVE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. FUTURE RESEARCH IN SUBSTANCE MISUSE AN OVERVIEVW PERSPECTIVE Michael Farrell PHRN Manchester 20th October 2006

  2. Political and moral values of the social system SERVICE Provider AND USER VIEW Research Evidence A model for evidence-based clinical decisions (from Haynes et al, 1996)

  3. Injecting

  4. HIV prevalence among IDUs in the EU EMCDDA 2004Notes: Colour indicates midpointsLocal data shown in ()

  5. HIV in IDUs in Europe • Marked difference between countries and within some countries • High prevalence countries (old MS) Italy, Spain, Portugal, followed by France • Some high prevalence estimates from new MS (Latvia, Estonia), and worries about others (Poland) • Low prevalence countries in both old and new MS including countries with high prevalence IDU • Cautious assessment is the long term trend appears to be stable or downwards • Some small increases in recent data in some countries or in specific subpopulations • Data quality problems so analysis must be made with caution

  6. A note on HCV prevalence in IDUs • Prevalence estimates higher and more convergent than for HIV • Clear need to finding effective prevention strategies • Routine disease surveillance sources of limited value • Drug injecting principle route of transmission for HCV in Europe

  7. Long term trend in acute drug-related deaths (1985-2003) 300 250 200 Index % (1985=100%) 150 100 50 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003* 100,0 104,5 118,7 136,9 153,7 181,0 216,4 223,5 201,8 212,2 225,4 252,4 230,1 235,6 241,1 255,4 240,1 205,8 194,9 INDEX EU 15, 1985 to 2003 index year 1985=100

  8. Introduction of MMT & NSP, 1967 to 2001(EU, Norway and Bulgaria)

  9. 450 400 350 300 250 200 150 100 50 0 LU UK ES IE MT FR PT IT SI DK EU DE NL NO SE EL BE CZ LT FI HU BG LV PL RO + 4 Estimated number of drug users in substitution treatment in 29 European countries (2003) per 100.000 population aged 15-64

  10. 600,000 537,000 500,000 400,000 351,000 265,000 300,000 207,000 200,000 73,400 100,000 0 1993 1995 1997 2000 2003 10-year trend in the number of substitution treatment clients in Europe (EU-15)

  11. Buprenorphine Other 20% 1% Methadone 79% Proportion of substitution drugs used in medically assisted treatment in Europe, 2003

  12. Prevalence of HIV in Injecting Drug Users some country estimates • European Union, Northern Europe low prevalence, Southern European countries higher prevalence but declining • Central and Eastern European countries upward trend, especially Ukraine, Russia, • USA and Canada generally stable low levels, outbreak Vancouver British Columbia related to cocaine injecting • Australia less than 2% • India Manipur Estimated at 50% plus • China Yunnan Province 10% to 70% in three years • Rapid increase in 31 provinces in China • Myanmar 56% IDUs HIV positive in one study • Vietnam 63% IDUs

  13. HIV prevalence in injecting drug users Myanmar Manipur & Yunnan Edinburgh Ho Chi Minh City Lithuania Bangkok Odessa Jakarta

  14. HIV infection rates in and out of substitution treatment (Metzger et al. 1993) Out % In %

  15. Drug Overdose and Mortality • Mean of 5+ non fatal overdoses in heroin using cohorts • Mortality 1 to 2% • In methadone treatment down to 0.2% • Recent Hser 33 year longitudinal study reports over 50% mortality in cohort • Suicide completion rates high and significant contributor to overall suicide

  16. The odds of a drug-related death in the first week of release among women • over 10times greater than that observed at one year (OR 10.6; 95%CI 4.8-22.0) • 70 times higher than age matched general population among men • around 8 times greater than at one year (OR 8.3: 95%CI 5.0-13.3). • 30 times higher than age matched general population (Singleton, Farrell et al 2003) • IN SUMMARY A 8-10 FOLD INCREASED RISK OF MORTALITY IN THE EARLY RELEASE PERIOD

  17. Substitution in prisons • Estimated that over 30 million imprisoned annually • Major risk for blood borne virus spread • In most countries where measured between one third and half have drug dependence • RCT of methadone in prison (Dolan et al) demonstrates role in reduction of blood borne virus, and general improvement, and post release reduction in mortality for those who continue • Rapid expansion in Europe in substitution in prisons • Huge challenge for Asia pacific region where insitutional incarceration standard response to opioid dependence • Consistently 90% relapse to heroin use, no studies on mortality

  18. Drug Substitution Treatment • Strong evidence for the benefits of oral methadone treatment RCTs +++ REASONABLE EFFECT SIZE • REDUCES DRUG CRIME .70 • REDUCES OPIATE CONSUMPTION .35 • REDUCES INJECTING & RISK TAKING 0.22 • Now good evidence for buprenorphine and LAAM RCTs ++ (LAAM CURRENTLY UNDER REVIEW) • Use of injectable diamorphine and other drugs building evidence base for comparative effectiveness, more dicussion on comparative cost effectiveness.

  19. Gunne & Gronbladh (1981) RCT:Methadone versus no methadone • 34 subjects using heroin by injection • 17 experimental (methadone) • 17 controls (no methadone) • Controls not allowed to enter MMT for 2 years • Followed up at 2 years and again at 4 years

  20. Gunne & Gronbladh (1981): Baseline

  21. Gunne & Gronbladh (1981): 2 years

  22. Gunne & Gronbladh (1981): 4 years

  23. A 33 year follow-up of narcotic addicts(Hser et al., 2001) 22% 2% 6% 7% 4% 48% 12% N 581 439 354 242 Age 24.5 (3.9) 36.8 (5.4) 47.6 (5.1) 57.4 (4.0)

  24. A 33 year follow-up of narcotic addicts(Hser et al., 2001) 22% 2% 6% 7% 4% 48% 12% N 581 439 354 242 Age 24.5 (3.9) 36.8 (5.4) 47.6 (5.1) 57.4 (4.0)

  25. COMPOSITE SLIDE3-Year Reincarceration Rates * * * *

  26. Methadone maintenance for prisoners Source: NSW DCS Inmate Census, UK Home Office, World Prison Population List 4th Ed, US Department of Justice

  27. NSW prison methadone program 1986 as a pilot pre release program by Department of Corrective Services (DCS) Criteria • 3-6 months prior to release • Past or present history of opiate dependence • History of returning to injecting and crime on previous releases • 3 designated community clinics 1990 those entering custody on MMT were continued Since 1990 12% NSW MMT received in custody

  28. NDARC Methadone Study NSW prison methadone maintenance • Randomised control trail of 384 IDUs in 1997 and re-interviewed in 1998 • Heroin use was significantly less for those receiving methadone, as measured by hair analysis. Source: Dolan & Wodak

  29. RCT Results MMT Control HCV incidence %24.3 31.7 Heroin (hair) %27 42 Heroin (SR) %33 78 No cases of HIV

  30. NDARC Methadone Study Follow up after release from gaol study of above 384 IDUs examining rate of: • Incarceration • Mortality • Hepatitis C

  31. Mortality rates (Intent)

  32. HCV incidence (Intent) Source: Dolan, K

  33. Re- incarceration up to May 2002 Source: Dolan, K

  34. Source: Dolan, K

  35. Need for upscaling of treatment • Urgent need in many regions for concerted effort to expand treatment • Discussions and research required on the challenge of upscaling • IDTS a major development within English Prisons • Major expansion in substitution treatment and psychosocial treatment

  36. NEED TO EVALUATE IDTS • Implementation assessment • Cost Effectiveness • Environmental Impact • Individual Outcome • Impact on Recidivism • Impact on Post Release Mortality

  37. Research Framework • Need pragmatic studies in prison context • More longitudinal studies • A 10 year mortality outcome study from the National Psychiatric Morbidity Survey • Consider a longitudinal Study of Young Offenders and exploration of trajectory of drug histories within the criminal justice system • Prisons ideal enviroments for exploration of issues of psychiatric comorbidity and substance use

  38. Studies linked to community studies • Linking treatment in prison up to the National Drug Treatment Monitoring System • Currently Outcomes Monitoring Project Underway, Important to have Prison Treatment Linked into this. • Infectious Diseases remain a big threat especially BBVs

  39. Conclusions • The huge challenge in all settings is to develop a comprehensive range of interventions that are humanitarian, effective and impactful for the all those who require interventions • To ensure that ethical and humane treatment is delivered as effectively as possible in all settings

More Related